## IN THE CLAIMS:

Claims 1-6, 8-48, and 50 are cancelled herein without prejudice or disclaimer. Claims 7 and 49 have been amended herein without prejudice or disclaimer. All of the pending claims 7 and 49 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

## **Listing of Claims:**

- 1.-6. (Canceled)
- 7. (Currently amended) A method of inducing tolerance in an <u>HA-1 negative</u>, <u>HLA-A2.1 positive</u> subject to transplants to prevent <u>or mitigate</u> rejection <u>of an HLA-matched graft</u> and/or Graft versus Host disease <del>or a method treating (auto)immune disease in a subject</del>, said method comprising:

repeatedly administering a tolerance-inducing dose of the preparation a peptide with a length of between 9 and 15 amino acid residues and comprising a sequence consisting of VLHDDLLEA (SEQ ID NO:2) of claim 4 to the subject.

- 8.-48. (Canceled)
- 49. (Currently amended) The method according to claim 7, wherein said <u>peptide</u> preparation is administered <u>orally</u>, intravenously, <u>intra-occularly</u>, or <u>intranasally</u>.
  - 50. (Canceled)